Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Pathogenica's HAI BioDetection Kit; Ariosa's Harmony Prenatal Test

Premium

Pathogenica has launched its HAI BioDetection Kit to detect hospital acquired infections using its DxSeq technology platform.

The kit uses next-gen sequencing to screen for 12 different pathogens and 15 resistance gene families in a single assay. Up to 12 patient samples can be tested at once, enabling dozens of samples to be tested in one day, according to the company.

The kit is marketed as research use only and is compatible with any sequencing platform. As part of its launch, the company has partnered with Life Technologies Japan to distribute the kit in Japan on the Ion Torrent platform.


Through a partnership with Laboratory Corporation of America, Ariosa Diagnostics has launched its Harmony Prenatal Test at select locations and will launch it more broadly in June. The noninvasive sequencing-based fetal trisomy test is available for women at least 10 weeks into their pregnancy with a single fetus conceived without the use of an egg donor. It is available for all women, regardless of risk of trisomy, the company said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more